insulin
High Strength, Fixed Combination and Biosimilar Insulin Products: Minimising the Risk of Medication Error
A new document has been posted on the NECS MO website.
High Strength, Fixed Combination and Biosimilar Insulin Products: Minimising the Risk of Medication Error. This is a briefing document which summarises the current guidance and recommendations on ways to minimise the risk of medication errors with newer insulin preparations.
Use of Abasaglar (Biosimilar Insulin Glargine)
The patent for Lantus® (Insulin glargine) has expired and a biosimilar preparation called Abasaglar®, which has a lower cost, has been launched. It has yet to be considered in the Local medicines decision making process, guidance for use with defined patient criteria is pending.